8-K: Cencora Reports Strong Second Quarter Results, Raises Full-Year EPS Guidance

Cencora's second quarter revenue increased by 7.8% year-over-year to $68.4 billion, with adjusted diluted EPS rising 8.6% to $3.80, leading to an increased full-year adjusted EPS guidance range.

Summary

• Cencora reported a 7.8% increase in revenue to $68.4 billion for the second quarter of fiscal year 2024, compared to the same period last year.
• GAAP diluted earnings per share (EPS) was $2.09, a slight decrease from $2.13 in the prior year's second quarter.
• Adjusted diluted EPS increased by 8.6% to $3.80, up from $3.50 in the prior year's second quarter.
• The company has raised its full-year adjusted diluted EPS guidance to a range of $13.30 to $13.50, up from the previous range of $13.25 to $13.50.
• U.S. Healthcare Solutions revenue increased by 8.1%, while International Healthcare Solutions revenue increased by 5.3%.
• Gross profit increased by 10.6% to $2.5 billion, primarily due to increases in both reportable segments and a LIFO credit.
• Operating expenses increased by 14.4% to $2.0 billion, driven by higher litigation and opioid-related expenses.
• The company's board of directors has authorized a new share repurchase program of up to $2.0 billion.
• A quarterly cash dividend of $0.51 per common share was declared, payable on May 24, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased adjusted EPS, and raised full-year guidance. While there are some negative aspects like increased expenses, the overall tone is optimistic and confident.

Positives

• Cencora experienced a significant increase in revenue, reaching $68.4 billion, a 7.8% increase year-over-year.
• Adjusted diluted EPS grew by 8.6% to $3.80, indicating strong profitability.
• The company raised its full-year adjusted diluted EPS guidance, reflecting confidence in future performance.
• Both U.S. and International Healthcare Solutions segments showed revenue growth.
• Gross profit increased by 10.6%, demonstrating improved profitability.
• The new share repurchase program of up to $2.0 billion could boost shareholder value.
• The declared quarterly cash dividend of $0.51 per share provides a return to shareholders.

Negatives

• GAAP diluted EPS decreased slightly by 1.9% to $2.09 compared to the prior year.
• Operating expenses increased by 14.4%, primarily due to higher litigation and opioid-related expenses.
• Operating income decreased by 1.3% due to increased expenses.
• The effective tax rate was 9.8% due to discrete tax benefits, which may not be sustainable.

Risks

• Increased litigation and opioid-related expenses significantly impacted operating expenses.
• The company faces potential risks related to changes in market conditions and pharmaceutical pricing.
• Fluctuations in foreign currency exchange rates could impact international revenue and operating income.
• The company's performance is subject to the risks and uncertainties detailed in its annual report on Form 10-K.

Future Outlook

Cencora has raised its full-year adjusted diluted EPS guidance to a range of $13.30 to $13.50. The company expects continued solid business performance for the full year, with International Healthcare Solutions segment revenue growth between 4% and 7%, and adjusted consolidated operating income growth between 9% and 11%. They also expect a higher effective tax rate of approximately 21% and weighted average diluted shares outstanding of approximately 201 to 202 million.

Management Comments

• Steven H. Collis, Chairman, President, and Chief Executive Officer, stated that Cencora's critical role in the healthcare and pharmaceutical supply chain was evident during the quarter.
• Mr. Collis also noted that the strong second quarter results and updated full-year guidance reflect the value Cencora delivers.
• He emphasized the company's focus on customer experience, innovation, and infrastructure investments to drive its pharmaceutical-centric strategy.

Industry Context

Cencora's performance reflects the ongoing demand for pharmaceutical distribution and healthcare solutions. The company's growth in both U.S. and international markets indicates a strong position in the global healthcare supply chain. The increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class highlights the impact of new drug categories on the industry.

Comparison to Industry Standards

• Cencora's 7.8% revenue growth is solid compared to other major pharmaceutical distributors, such as McKesson and Cardinal Health, which have also reported mid-single-digit revenue growth in recent quarters.
• The 8.6% increase in adjusted diluted EPS is competitive, indicating effective cost management and operational efficiency.
• The company's focus on specialty products and international expansion aligns with industry trends, where these areas are seen as key growth drivers.
• Cencora's adjusted operating income growth of 10.9% is a strong performance compared to industry averages, which often see single-digit growth.
• The share repurchase program is a common practice among large public companies to enhance shareholder value, and Cencora's $2 billion program is significant.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased adjusted EPS guidance, the new share repurchase program, and the declared dividend.
• Employees will be impacted by the leadership changes and the company's focus on innovation and growth.
• Customers will benefit from Cencora's continued focus on providing reliable pharmaceutical solutions.
• Suppliers will continue to partner with Cencora in the pharmaceutical supply chain.

Next Steps

• The company will host a conference call to discuss its operating results on May 1, 2024.
• Cencora management will attend the Leerink Healthcare Crossroads Conference on May 30, 2024.
• The company will continue to execute its pharmaceutical-centric strategy and invest in infrastructure.

Key Dates

Keywords

Cencora, pharmaceutical, healthcare, revenue, EPS, earnings, guidance, share repurchase, dividend, operating income